AI Article Synopsis
Article Abstract
Background: Assessment of nigrostriatal degeneration is a key element to discriminate between dementia with Lewy bodies (DLB) and Alzheimer disease (AD), and it is often evaluated using ioflupane (I-FP-CIT) single-photon emission computed tomography (SPECT). Given the limited availability of I-FP-CIT SPECT, we evaluated if a mask-based approach to nigroputaminal magnetic resonance imaging (MRI) diffusion-weighted tractography could be able to capture microstructural changes reflecting nigroputaminal degeneration in DLB.
Methods: A nigroputaminal bundle mask was delineated on 12 healthy volunteers (HV) and applied to MRI diffusion-weighted data of 18 subjects with DLB, 21 subjects with AD and another group of 12 HV. The correlation between nigroputaminal fractional anisotropy (FA) values and I-FP-CIT SPECT findings was investigated. Shapiro-Wilk, ANOVA, ANCOVA, and parametric correlation statistics as well as receiver operating characteristic (ROC) analysis were used.
Results: DLB patients showed a higher nigroputaminal FA values compared with both AD and HV-controls groups (p = 0.001 for both comparisons), while no difference was observed between HV-controls and AD groups (p = 0.450); at ROC analysis, the area under the curve for the discriminating DLB and AD subjects was 0.820; FA values correlated with I-FP-CIT values (on the left, r = -0.670; on the right, r = -720). No significant differences were observed for the FA of the corticospinal tract across the three groups (p = 0.740).
Conclusions: In DLB, nigroputaminal degeneration could be reliably assessed on MRI diffusion scans using a mask of nigroputaminal bundle trajectory. Nigroputaminal FA in DLB patients correlated with I-FP-CIT values data may allow to differentiate these patients from AD patients and HV-controls.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196565 | PMC |
| http://dx.doi.org/10.1186/s41747-020-00153-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neural substrates underlying distinct dual cognitive syndromes in Parkinson's disease.
Eur J Neurol
January 2025
Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Background: A dual-syndrome hypothesis, which states the cognitive impairments in Parkinson's disease (PD) are attributable to frontostriatal dopaminergic dysregulation and cortical disturbance-each associated with attention/executive and memory/visuospatial dysfunction, respectively-has been widely accepted. This multisystem contribution also underlies highly heterogeneous progression rate to dementia.
Methods: Nondemented PD patients who underwent [I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ([I]FP-CIT) SPECT and neuropsychological examinations were enrolled.
Striatal Dopaminergic Function and Motor Slowing in Essential Tremor Plus.
Mov Disord Clin Pract
December 2024
Clinical Neurosciences, University of Turku, Turku, Finland.
Background: While previous imaging studies have generally shown normal striatal dopamine transporter (DAT) binding in essential tremor (ET), emerging evidence suggests a partial dopaminergic mechanism in this condition and an epidemiological link between ET and Parkinson's disease (PD). This link seems particularly meaningful in ET patients with additional neurological signs, such as slowness of movements, rigidity, or rest tremor (ET+).
Objectives: To investigate the potential dopaminergic pathophysiology of ET+ and to compare it to PD.
Exploring the relation between REM sleep behavior disorder onset and striatal dopaminergic dysfunction in Parkinson's Disease.
J Neurol
December 2024
Department "G.F. Ingrassia", Section of Neurosciences, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
Background: The α-Synuclein Origin and Connectome (SOC) model recently proposed two different Parkinson's Disease (PD) phenotypes clinically based on the relationship between REM sleep behavior disorder (RBD) and motor symptoms' onset: a "body first" phenotype and a "brain first" phenotype in which RBD precedes or may follow the motor onset, respectively. A higher burden of non-motor symptoms as well as a more symmetrical clinical presentation have also been predicted in the body-first phenotype. This point has been poorly assessed through semi-quantitative striatal dopaminergic functional imaging to date.
View Article and Find Full Text PDFReliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion.
Eur J Nucl Med Mol Imaging
November 2024
Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Purpose: This study examined the impact of venlafaxine and bupropion on the detection of nigrostriatal degeneration by dopamine transporter (DAT)-SPECT.
Methods: 43 patients (70.7 ± 8.
Longitudinal decline in DAT binding in Parkinson's disease: connections with sleep disturbances.
BMC Med
November 2024
Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou , Zhejiang, 310009, China.
Article Synopsis
- The study examined how the dysfunction of the nigrostriatal dopamine system affects sleep disturbances in newly diagnosed Parkinson's disease patients, focusing on excessive daytime sleepiness and probable RBD.
- Data was collected from 621 patients over four years through established sleep scales and dopamine transporter imaging.
- Results showed a negative correlation between dopamine transporter binding ratios and sleep issues, suggesting that dopamine dysfunction and genetic factors (like the alpha-synuclein gene) significantly contribute to sleep disturbances in these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!